I am an enthusiastic and motivated storyteller with six years of experience in market access and behavioral health. Throughout my career,
I have thoroughly understood various rare diseases and complex medical conditions. I actively leverage my real-world experience across different healthcare settings to navigate the complex landscapes of research, clinical trials, FDA approvals, and the insurance challenges encountered in both commercial and Medicare/Medicaid spheres.
Professional Portfolio
Payer Facing Materials
Streamlined Payer Value Prop: A succinct version of the traditionally long-form value proposition is to communicate with payers that KEVZARA offers a viable treatment option for adult patients with polymyalgia rheumatica (PMR).
Payer Value Propr for Specialty Pharmacies: A communication was created to identify to specialty pharmacy stakeholders the unique value proposition offered by KEVZARA to patients with PMR. Most importantly, the ability for KEVZARA to reduce glucocorticoid burden.
Payer Value Propr for Specialty Pharmacies: A communication was created to identify to specialty pharmacy stakeholders the unique value proposition offered by KEVZARA to patients with PMR. Most importantly, the ability for KEVZARA to reduce glucocorticoid burden.
Patient and HCP Facing Materials
This brochure covers product information and acquisition information for LYNOZYFIC.
This guide provides information for HCPs to access relevant billing and coding information for LYNOZYFIC.
This patient enrollment brochure was created to provide the latest information on Medicare coverage. The brochure includes enrollment parameters for Medicare patients. In addition, the brochure provides context on recent changes to Medicare coverage that were made based on the Inflation Reduction Act (IRA).